Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct;237(10):3778-3787.
doi: 10.1002/jcp.30851. Epub 2022 Aug 11.

Sodium-glucose co-transporter 2 inhibitors and hematopoiesis

Habib Yaribeygi  1 , Mina Maleki  2 , Fatemeh Nasimi  1 , Alexandra E Butler  3 , Tannaz Jamialahmadi  4   5 , Amirhossein Sahebkar  4   6   7   8
Affiliations
Review

Sodium-glucose co-transporter 2 inhibitors and hematopoiesis

Habib Yaribeygi et al. J Cell Physiol. 2022 Oct.

Abstract

Many patients with diabetes mellitus, especially those with chronic kidney disorders, have some degree of anemia due to a spectrum of causes and underlying pathophysiologic pathways. As such, enhancement in erythropoiesis is important in these patients. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a relatively new class of antidiabetic drugs with confirmed protective effects in kidney and cardiovascular tissues. Recent evidence suggests that these drugs may provide additional benefits in enhancing hematopoietic processes in diabetic patients. Though the exact mediating pathways have not been fully elucidated, cellular mechanisms are likely involved. In the current study, we present the potential pathways by which SGLT2i may modulate hematopoiesis and stimulate erythropoiesis.

Keywords: chronic kidney disease; diabetes mellitus; erythropoietin; hematopoiesis; ketone body; sodium-glucose co-transporter 2 inhibitors.

PubMed Disclaimer

References

REFERENCES

    1. Albiero, M., Tedesco, S., Amendolagine, F. I., D'Anna, M., Migliozzi, L., Zuccolotto, G., Rosato, A., Cappellari, R., Avogaro, A., & Fadini, G. P. (2021). Inhibition of SGLT-2 rescues bone marrow cell traffic for vascular repair. Role of glucose control and ketogenesis. Diabetes, 70, 1767-1779.
    1. Barrett, K. E., Boitano, S., Barman, S. M., & Brooks, H. L. (2010). Ganong's review of medical physiology twenty.
    1. Bessho, R., Takiyama, Y., Takiyama, T., Kitsunai, H., Takeda, Y., Sakagami, H., & Ota, T. (2019). Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. Scientific Reports, 9(1), 1-12.
    1. Bissinger, R., Bhuyan, A. A. M., Qadri, S. M., & Lang, F. (2019). Oxidative stress, eryptosis and anemia: A pivotal mechanistic nexus in systemic diseases. The FEBS Journal, 286(5), 826-854.
    1. Bonora, B. M., Avogaro, A., & Fadini, G. P. (2020). Extraglycemic effects of SGLT2 inhibitors: A review of the evidence. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13, 161-174.

LinkOut - more resources